Matches in UGent Biblio for { <https://biblio.ugent.be/publication/845856#aggregation> ?p ?o. }
Showing items 1 to 43 of
43
with 100 items per page.
- aggregation classification "A1".
- aggregation creator B328911.
- aggregation creator B328912.
- aggregation creator B328913.
- aggregation creator B328914.
- aggregation creator B328915.
- aggregation creator B328916.
- aggregation creator B328917.
- aggregation creator B328918.
- aggregation creator B328919.
- aggregation creator B328920.
- aggregation creator B328921.
- aggregation creator person.
- aggregation date "2009".
- aggregation format "application/pdf".
- aggregation hasFormat 845856.bibtex.
- aggregation hasFormat 845856.csv.
- aggregation hasFormat 845856.dc.
- aggregation hasFormat 845856.didl.
- aggregation hasFormat 845856.doc.
- aggregation hasFormat 845856.json.
- aggregation hasFormat 845856.mets.
- aggregation hasFormat 845856.mods.
- aggregation hasFormat 845856.rdf.
- aggregation hasFormat 845856.ris.
- aggregation hasFormat 845856.txt.
- aggregation hasFormat 845856.xls.
- aggregation hasFormat 845856.yaml.
- aggregation isPartOf urn:issn:0004-3591.
- aggregation language "eng".
- aggregation publisher "Wiley-Liss".
- aggregation subject "Medicine and Health Sciences".
- aggregation title "Improvement in hemoglobin levels in patients with ankylosing spondylitis treated with Infliximab".
- aggregation abstract "Objective. Anemia is a common complication in patients with inflammatory diseases such as ankylosing spondylitis (AS). This post hoc analysis of a large, randomized, placebo-controlled trial examined the effect of infliximab on hemoglobin levels, physical function, and fatigue in patients with AS. Methods. Patients received infliximab 5 mg/kg (n = 188) or placebo (n = 68) at weeks 0, 2, 6, 12, and 18. Hemoglobin, interleukin-6 (IL-6), and C-reactive protein (CRP) levels, fatigue (visual analog scale [VAS]), physical function (Bath Ankylosing Spondylitis Functional Index [BASFI]) and disease activity were evaluated at baseline and week 24. Anemia was defined as a hemoglobin level <12 gm/dl for women and <13 gm/dl for men. Results. At baseline, 11 placebo group patients (16.2%) and 37 infliximab group patients (19.7%) had anemia. Of these, more infliximab-treated patients achieved normal hemoglobin levels at week 24 compared with patients receiving placebo (70.3% versus 27.3%; P = 0.0155). Infliximab-treated patients had significant improvements in mean hemoglobin concentration (0.7 gm/dl versus -0.3 gm/dl), BASFI score (-2.1 versus -0.2), and fatigue VAS score (-2.4 versus -0.4) compared with placebo patients (P < 0.001). Multiple regression analyses showed that improvements in hemoglobin level were significantly and independently associated with improvements in physical function and fatigue. Infliximab-treated patients with elevated CRP or IL-6 levels at baseline were more likely than those with low levels to have improvement in hemoglobin levels. Conclusion. Infliximab treatment significantly decreased the proportion of AS patients with anemia and improved hemoglobin levels compared with placebo. Improvement in hemoglobin level was independently associated with improvements in physical function and fatigue.".
- aggregation authorList BK620320.
- aggregation endPage "1036".
- aggregation issue "8".
- aggregation startPage "1032".
- aggregation volume "61".
- aggregation aggregates 848343.
- aggregation isDescribedBy 845856.
- aggregation similarTo art.24865.
- aggregation similarTo LU-845856.